According to Sunovion Pharmaceuticals, Zetonna ciclesonide nasal aerosol for the treatment of perennial and seasonal allergic rhinitis is now available throughout the US. The company announced in May that it would launch the product by this fall. Sunovion also markets Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis and Alvesco ciclesonide … [Read more...] about Sunovion launches Zetonna nasal aerosol in US
News
Quintiles to promote Almirall respiratory products in UK, beginning with Eklira Genuair
Quintiles will promote respiratory drugs from Almirall in the UK, starting with the newly approved Eklira Genuair aclidinium bromide dry powder inhaler for the treatment of COPD. Quintiles performed some of the clinical study work for the product. Menarini will market the DPI in most of Europe as Bretaris Genuair. Almirall UK General Manager Carlos Gallardo … [Read more...] about Quintiles to promote Almirall respiratory products in UK, beginning with Eklira Genuair
Health Canada issues advisory on potential Pulmicort Turbuhaler device failure
Health Canada has issued an advisory to health care professionals that "AstraZeneca Canada has received a small number of product complaints for Pulmicort Turbuhaler, 200 µg per metered dose (200 doses) regarding the malfunction of the delivery device that results in a failure to dispense the dose of medication." According to the notice, the devices sometimes fail to … [Read more...] about Health Canada issues advisory on potential Pulmicort Turbuhaler device failure
Unigene responds to EMA recommendation against use of calcitonin nasal spray
Unigene Laboratories, which manufactures Fortical calcitonin nasal spray for the treatment of osteoporosis, has requested product safety data submitted to the EMA's Committee for Medicinal Products for Human Use (CHMP) in response to the EMA's recommendation against use of calcitonin nasal sprays. The EMA report, issued on July 19, 2012, notes a 2.4% increase in the … [Read more...] about Unigene responds to EMA recommendation against use of calcitonin nasal spray
All UK children to receive nasal flu vaccine free of charge — eventually
The UK Department of Health has announced that Health Secretary Andrew Lansley has agreed to a flu vaccination program recommended by a committee of independent experts that will provide MedImmune's Fluenz intranasal vaccine to all children aged 2 to 17 at no cost. Fluenz is known as FluMist in the US. Asthmatic children and those with other risk factors were already … [Read more...] about All UK children to receive nasal flu vaccine free of charge — eventually
Eklira/Bretaris Genuair aclidinium bromide DPI gets approval in Europe
Just after announcing the approval of the Tudorza Pressair aclidinium bromide dry powder inhaler for the treatment of COPD in the US, Almirall has announced that the European Commission has granted marketing approval to its aclidinium DPI, which will be marketed as the Eklira or Bretaris Genuair in Europe. The approval applies to all EU member states, Iceland and … [Read more...] about Eklira/Bretaris Genuair aclidinium bromide DPI gets approval in Europe
“Asthma Inhalers Relief Act of 2012” aims to allow sales of remaining CFC inhalers
The US House of Representatives held a meeting on July 18, 2012 regarding the "Asthma Inhalers Relief Act of 2012," which is intended "To direct the Administrator of the Environmental Protection Agency to allow for the distribution, sale, and consumption in the United States of remaining inventories of over-the-counter CFC epinephrine inhalers." Witnesses who … [Read more...] about “Asthma Inhalers Relief Act of 2012” aims to allow sales of remaining CFC inhalers
FDA approves Tudorza Pressair aclidinium bromide DPI
The FDA has approved the Tudorza Pressair aclidinium bromide dry powder inhaler for the treatment of COPD. The DPI will be distributed by Forest Pharmaceuticals, a division of Forest Laboratories, which licensed US rights to the product from Almirall. Forest says that it expects wholesalers to have the product in the fourth quarter of 2012. Almirall President Jorge … [Read more...] about FDA approves Tudorza Pressair aclidinium bromide DPI
Alexza gets $20 million in new funding
Alexza Pharmaceuticals has announced that it has issued 80,429 shares of common stock to Azimuth Opportunity as the two companies have reached an agreement for a committed equity financing facility under which Alexza has the option to sell Azimuth up to $20 million of its registered common stock over 2 years. The two companies entered a similar agreement in May 2010 … [Read more...] about Alexza gets $20 million in new funding
UK supermarket chain to begin selling inhalers over the counter
Supermarket chain Asda says that it will become the first retailer in the UK to sell asthma reliever inhalers over the counter when its pharmacies begin offering salbutamol (albuterol) inhalers for sale on July 24. Asda has pharmacies in 218 stores. Patients over the age of 16 will be able to purchase two inhalers for £7 after filling out a simple questionnaire. … [Read more...] about UK supermarket chain to begin selling inhalers over the counter